2020-09-01

1: Watanabe T, Ohtani T, Aihara M, Ishiuchi S. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models. J Neurosurg. 2013 Jan 11. [Epub ahead of print] PubMed PMID: 23311938.

2: Torres LA, Barbarroja N, Dorado G, Velasco F, López-Pedrera C. VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications. Br J Haematol. 2009 Jun;145(6):836-8. doi: 10.1111/j.1365-2141.2009.07673.x. Epub 2009 Apr 8. PubMed PMID: 19388942.

3: Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, Tanaka H, Shibayama H, Sugahara H, Takai E, Zhang X, Machii T, Kanakura Y. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int J Hematol. 2002 Dec;76(5):427-35. PubMed PMID: 12512837.

4: Kovalenko M, Rönnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Levitzki A, Böhmer FD. Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry. 1997 May 27;36(21):6260-9. PubMed PMID: 9174341.